Q2 revenue rose 12%, but exceptional charges cut consolidated profit by 36%

EBITDA margin compressionExceptional itemResults View source PDF Explain this filing

SUNPHARMA · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

+1.1%Reaction day

₹1758.10

prior close

₹1796.60

announcement price

In-mkt

timing

Nifty 100market+0.3%+0.8% vs market

Pharmaceuticals peers, median of 173sector-0.8%+1.9% vs sector

On the reaction day the stock moved 0.8 pts more than Nifty 100 and 1.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

-0.1

10m

-0.6

15m

+1.3

30m

+2.2

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

+1.1+0.3+0.8-0.8+1.9

Next day

+0.3+2.0-1.7-0.8+1.1

+1.0+3.5-2.5-0.5+1.5

+1.1+4.4-3.3+0.3+0.8

+4.4+6.7-2.2+1.3+3.1

+5.8pendingpending+1.3+4.5

—————

15d

—————

UpDownMarket · Nifty 100Sector · Pharmaceuticals peers, median of 173Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated September 2026 quarter revenue rose 11.9% and profit after tax fell 36.4% year on year, to Rs161.99bn and Rs19.89bn respectively. Exceptional charges of Rs12.69bn included a Rs9.23bn US drug-pricing settlement and Rs3.46bn of Organon acquisition costs. Half-year revenue rose 11.2% to Rs314.99bn, while profit after tax fell 9.5% to Rs48.83bn. Operating cash flow was positive at Rs31.41bn. The auditor review was clean.

Likely market impact

Revenue and underlying profit grew, but legal and deal charges hit reported earnings. The stock may stay weak near term despite positive cash flow.

By the numbersConsolidated · Q2 FY27 vs Q2 FY26

	Q2 FY27	Q2 FY26	Change
Revenue	₹16,199 Cr	₹14,478 Cr	+11.9%
Operating profit	₹3,911 Cr	₹3,698 Cr	+5.8%
Profit after tax	₹1,995 Cr	₹3,125 Cr	−36.2%
EBITDA margin	21.4%	31.3%	−9.8 pp

From the company's XBRL filing, not from the text above. Operating profit = profit before tax − exceptional items − other income. EBITDA = profit before tax + finance costs + depreciation − other income.